

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bayzed Health Group Inc
佰澤醫療集團

(Incorporated under the laws of the Cayman Islands with limited liability)
(Stock Code: 2609)

VOLUNTARY ANNOUNCEMENT
INCLUSION OF THE COMPANY AS A CONSTITUENT OF
THE HANG SENG INDEX SERIES

This announcement is made by Bayzed Health Group Inc (the “**Company**”, together with its subsidiaries collectively referred to as the “**Group**”) on a voluntary basis, the purpose of which is to inform the shareholders and potential investors of the Company of the latest business development of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, pursuant to the quarterly review results of the Hang Seng Index Series published by Hang Seng Indexes Company Limited on August 22, 2025, the Company has been selected and will be included as a constituent of the Hang Seng Index Series, including but not limited to the following, with effect from September 8, 2025:

1. Hang Seng Composite Index;
2. Hang Seng Composite Industry Index – Healthcare;
3. Hang Seng Composite MidCap & SmallCap Index;
4. Hang Seng Composite SmallCap Index;
5. Hang Seng Healthcare Index;
6. Hang Seng SCHK Healthcare Equipment & Services (Investable) Index; and
7. Hang Seng SCHK Healthcare Equipment & Services Index.

The Hang Seng Composite Index covers the top 95% of the total market capitalization of companies listed on the Main Board of The Stock Exchange of Hong Kong Limited, serving as a comprehensive benchmark for the Hong Kong market. The Hang Seng Composite Index may be used as a benchmark for the issuance of index funds, mutual funds and performance measurement. The Company's inclusion in the Hang Seng Composite Index will qualify its shares for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect (channels for stock trading between Hong Kong and mainland Chinese investors).

The Board believes that the Company's inclusion in the Hang Seng Composite Index and the aforementioned indices reflects growing recognition from investors regarding the Group's operational performance, investment value, and development potential. This is expected to enhance the Company's visibility in the capital market, improve the liquidity of trading in the Company's shares, and further enhance the Company's investment value.

The Board wishes to express its sincere gratitude to the Company's shareholders and investors for their ongoing support. The Company will continue to leverage its competitive advantages, diligently develop its business, and strive to become a leading full-cycle oncology healthcare group in China, thereby creating value for its shareholders.

By order of the Board
Bayzed Health Group Inc
(佰澤醫療集團)
Mr. Zhao Yongkai
Chairman and Executive Director

Hong Kong, August 22, 2025

As at the date of this announcement, directors of the Company include Mr. Zhao Yongkai, Ms. Xu Xu, Dr. Chen Haoyang, Mr. Lu Jizhong and Mr. Feng Yu as executive directors; and Mr. Chan Hok Leung, Ms. Liu Shuang and Dr. Guo Wei as independent non-executive directors.